RESUMEN
BACKGROUND: Trauma and emergency surgery are major causes of morbidity and mortality. The objective of this study was to determine whether serum levels of epinephrine and norepinephrine are associated with aging and mortality. METHODS: This was a prospective observational cohort study conducted in a surgical critical care unit. We included 90 patients who were admitted for postoperative care, because of major trauma, or both. We collected demographic and clinical variables, as well as serum levels of epinephrine and norepinephrine. RESULTS: For patients in the > 60-year age group, the use of vasoactive drugs was found to be associated with an undetectable epinephrine level (OR [95% CI] = 6.36 [1.12, 36.08]), p = 0.05). For the patients with undetectable epinephrine levels, the in-hospital mortality was higher among those with a norepinephrine level ≥ 2006.5 pg/mL (OR [95% CI] = 4.00 [1.27, 12.58]), p = 0.03). CONCLUSIONS: There is an association between age and mortality. Undetectable serum epinephrine, which is more common in older patients, could contribute to poor outcomes. The use of epinephrine might improve the clinical prognosis in older surgical patients with shock.
RESUMEN
Septic shock typically requires the administration of vasopressors. Adrenergic agents remain the first choice, namely norepinephrine. However, their use to counteract life-threatening hypotension comes with potential adverse effects, so that non-adrenergic vasopressors may also be considered. The use of agents that act through different mechanisms may also provide an advantage. Nitric oxide (NO) is the main driver of the vasodilation that leads to hypotension in septic shock, so several agents have been tested to counteract its effects. The use of non-selective NO synthase inhibitors has been of questionable benefit. Methylene blue, an inhibitor of soluble guanylate cyclase, an important enzyme involved in the NO signaling pathway in the vascular smooth muscle cell, has also been proposed. However, more than 25 years since the first clinical evaluation of MB administration in septic shock, the safety and benefits of its use are still not fully established, and it should not be used routinely in clinical practice until further evidence of its efficacy is available.
Asunto(s)
Hipotensión , Choque Séptico , Humanos , Azul de Metileno/efectos adversos , Choque Séptico/tratamiento farmacológico , Choque Séptico/metabolismo , Hipotensión/tratamiento farmacológico , Guanilil Ciclasa Soluble , Norepinefrina , Vasoconstrictores/efectos adversosRESUMEN
BACKGROUND: The clinical picture of coronavirus disease 2019 (COVID-19)-associated sepsis is similar to that of sepsis of other aetiologies. The present study aims to analyse the role of syndecan-1 (SDC-1) as a potential predictor of septic shock in critically ill patients with COVID-19. METHODS: This is a prospective study of 86 critically ill patients due to COVID-19 infection. Patients were followed until day 28 of hospitalization. Vascular biomarkers, such as vascular cell adhesion protein-1, SDC-1, angiopoietin-1 and angiopoietin-2, were quantified upon admission and associated with the need for vasopressors in the first 7 d of hospitalization. RESULTS: A total of 86 patients with COVID-19 (mean age 60±16 y; 51 men [59%]) were evaluated. Thirty-six (42%) patients died during hospitalization and 50 (58%) survived. The group receiving vasopressors had higher levels of D-dimer (2.46 ng/ml [interquartile range {IQR} 0.6-6.1] vs 1.01 ng/ml [IQR 0.62-2.6], p=0.019) and lactate dehydrogenase (929±382 U/l vs 766±312 U/l, p=0.048). The frequency of deaths during hospitalization was higher in the group that received vasoactive amines in the first 24 h in the intensive care unit (70% vs 30%, p=0.002). SDC-1 levels were independently associated with the need for vasoactive amines, and admission values >269 ng/ml (95% CI 0.524 to 0.758, p=0.024) were able to predict the need for vasopressors during the 7 d following admission. CONCLUSIONS: Syndecan-1 levels predict septic shock in critically ill patients with COVID-19.
Asunto(s)
COVID-19 , Sepsis , Choque Séptico , Masculino , Humanos , Adulto , Persona de Mediana Edad , Anciano , Estudios Prospectivos , Sindecano-1 , Enfermedad Crítica , COVID-19/complicaciones , AminasRESUMEN
ABSTRACT BACKGROUND: Hematopoietic stem cell transplantation (HSCT) recipients requiring intensive care unit (ICU) admission early after transplantation have a poor prognosis. However, many studies have only focused on allogeneic HSCT recipients. OBJECTIVES: To describe the characteristics of HSCT recipients admitted to the ICU shortly after transplantation and assess differences in 1-year mortality between autologous and allogeneic HSCT recipients. DESIGN AND SETTING: A single-center retrospective cohort study in a cancer center in Brazil. METHODS: We included all consecutive patients who underwent HSCT less than a year before ICU admission between 2009 and 2018. We collected clinical and demographic data and assessed the 1-year mortality of all patients. The effect of allogeneic HSCT compared with autologous HSCT on 1-year mortality risk was evaluated in an unadjusted model and an adjusted Cox proportional hazard model for age and Sequential Organ Failure Assessment (SOFA) at admission. RESULTS: Of the 942 patients who underwent HSCT during the study period, 83 (8.8%) were included in the study (autologous HSCT = 57 [68.7%], allogeneic HSCT = 26 [31.3%]). At 1 year after ICU admission, 21 (36.8%) and 18 (69.2%) patients who underwent autologous and allogeneic HSCT, respectively, had died. Allogeneic HSCT was associated with increased 1-year mortality (unadjusted hazard ratio, HR = 2.79 [confidence interval, CI, 95%, 1.48-5.26]; adjusted HR = 2.62 [CI 95%, 1.29-5.31]). CONCLUSION: Allogeneic HSCT recipients admitted to the ICU had higher short- and long-term mortality rates than autologous HSCT recipients, even after adjusting for age and severity at ICU admission.
RESUMEN
The hemodynamic instability in the pregnant patient is a challenge for the treating team, due to the physiological peculiarities of her condition and the emotional impact of her care. Considering the increase in the mortality of pregnant women worldwide in developed countries due to múltiple factors associated with an inadequate level of care, anesthesiologists have an essential role within this team. Early recognition and timely treatment of a pregnant or postpartum patient is required. The evaluation of the hemodynamic status only with the clinic in changing situations may be insufficient in the obstetric patient for an adequate management, especially in pathophysiological conditions and with the impact of the pharmacological action of anesthesia. Therefore, monitoring at the patient's bedside, mainly through monitoring of cardiac output (CO), myocardial response and volemia status with minimally invasive cardiac output monitors, cardiac and pulmonary ultrasound evaluation allow a management that has an impact on survival.
La inestabilidad hemodinámica en la paciente gestante constituye un desafío para el equipo tratante, por las peculiaridades fisiológicas que ofrece su condición y por el impacto emocional que genera su atención. Considerando el aumento de la mortalidad de la embarazada a nivel mundial en países desarrollados debido a factores múltiples asociados a un nivel de cuidados no adecuados, es que los anestesiólogos cumplen un rol fundamental dentro de este equipo. Se requiere la detección precoz y tratamiento oportuno de una paciente gestante o puérpera. La evaluación del estado hemodinámico solo con la clínica en situaciones cambiantes puede ser insuficiente en la paciente obstétrica para un adecuado enfrentamiento, especialmente en condiciones fisiopatológicas y con impacto de la acción farmacológica de la anestesia. Es por esto que la monitorización al lado del paciente, principalmente a través de la vigilancia del gasto cardíaco (GC); la respuesta miocárdica y el estado de la volemia con monitores de gasto cardíaco mínimamente invasivos; la evaluación ecográfica cardíaca y pulmonar permiten un enfrentamiento que impacta en la sobrevida.
Asunto(s)
Humanos , Femenino , Embarazo , Monitorización Hemodinámica , Hemodinámica/fisiología , Obstetricia/métodos , Gasto Cardíaco/fisiologíaRESUMEN
Abstract Introduction Vasopressors are essential in the management of various types of shock. Objective To establish the trend of vasopressors use in the intensive care units (ICU) in a population of patients affiliated with the Colombian Health System, 2010-2017. Methods Observational trial using a population database of patients hospitalized in eleven ICUs in various cities in Colombia. The drugs dispensed to hospitalized patients over 18 years old, from January 2010 until December 2017 were considered. A review and analysis of the vasopressors dispensed per month was conducted, taking into account sociodemographic and pharmacological variables (vasopressor used and daily doses defined per 100/beds/day (DBD). Results 81,348 dispensations of vasopressors, equivalent to 26,414 treatments in 19,186 patients receiving care in 11 hospitals from 7 cities were reviewed. The mean age of patients was 66.3±18.1 years and 52.6 % were males. Of the total number of treatments recorded, 17,658 (66.8 %) were with just one vasopressor. Norepinephrine was the most frequently prescribed drug (75.9 % of the prescriptions dispensed; 60.5 DBD), followed by adrenaline (26.6 %; 41.6 DBD), dopamine (19.4%), dobutamine (16.0 %), vasopressin (8.5 %) and phenylephrine (0.9 %). The use of norepinephrine increased from 2010 to 2017 (+6.19 DBD), whilst the use of other drugs decreased, particularly the use of adrenaline (-60.6 DBD) and dopamine (-10.8 DBD). Conclusions Norepinephrine is the most widely used vasopressor showing a growing trend in terms of its use during the study period, which is supported by evidence in favor of its effectiveness and safety in patients with shock.
Resumen Introducción Los fármacos vasopresores son fundamentales en el manejo de los diferentes tipos de choque. Objetivo Determinar la tendencia de utilización de fármacos vasopresores en unidades de cuidados intensivos (UCI) en una población de pacientes afiliados al Sistema de Salud de Colombia, 2010-2017. Métodos Estudio observacional, a partir de una base de datos poblacional con pacientes hospitalizados en once UCI de diferentes ciudades de Colombia. Se obtuvieron las dispensaciones de pacientes mayores de 18 años hospitalizados desde enero de 2010 hasta diciembre de 2017. Se hizo revisión y análisis de la dispensación mensual de vasopresores. Se consideraron variables sociodemográficas y farmacológicas (medicamento vasopresor usado y dosis diarias definidas por 100 camas/día [DCD]). Resultados Se revisaron 81.348 dispensaciones de vasopresores, equivalentes a 26.414 terapias en 19.186 pacientes atendidos en 11 hospitales de 7 ciudades, cuya edad promedio fue 66,3±18,1 años y el 52,6 % eran hombres. Del total de terapias registradas, 17.658 (66,8 %) fueron con un solo vasopresor. La norepinefrina fue el más comúnmente prescrito (75,9 % de las dispensaciones; 60,5 DCD), seguido por adrenalina (26,6 %; 41,6 DCD), dopamina (19,4 %), dobutamina (16,0 %), vasopresina (8,5 %) y fenilefrina (0,9 %). El uso de norepinefrina se incrementó de 2010 a 2017 (+6,19 DCD), mientras que el de otros fármacos disminuyó, especialmente adrenalina (-60,6 DCD) y dopamina (-10,8 DCD). Conclusiones La norepinefrina es el fármaco vasopresor más utilizado y el que ha demostrado una tendencia de uso incremental durante el periodo de estudio, lo cual está respaldado por evidencia a favor de su efectividad y seguridad en pacientes con choque.
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Anciano , Choque , Vasoconstrictores , Vasopresinas , Unidades de Cuidados Intensivos , Fenilefrina , Preparaciones Farmacéuticas , Dopamina , Epinefrina , Norepinefrina , Dobutamina , Utilización de Medicamentos , Dosificación , PrescripcionesRESUMEN
OBJECTIVE: To evaluate the impact of early disseminated intravascular coagulation (DIC) on illness severity in children using a database of emergency department ED encounters for children with suspected sepsis, in view of similar associations in adults. STUDY DESIGN: Laboratory and clinical data were extracted from a registry of emergency department encounters of children with suspected sepsis between April 1, 2012, and June 26, 2017. International Society of Thrombosis and Hemostasis DIC scores were calculated from laboratory values obtained within 24 hours of emergency department admission. Univariate logistic regression, multivariable logistic regression, and Cox regression were used to assess the influence of DIC scores on vasopressor use (primary outcome), mortality, ventilator requirement, pediatric intensive care unit admission, and hospital duration (secondary outcomes). The optimal DIC score cutoff for outcome prediction was determined. RESULTS: Of 1653 eligible patients, 284 had DIC scores within 24 hours, including 92 who required vasopressors and 23 who died within 1 year. An initial DIC score of ≥3 was the most sensitive and specific DIC score for predicting adverse outcomes. Those with a DIC score of ≥3 vs <3 had increased odds of vasopressor use in both univariate (OR, 4.48; 95% CI, 2.63-7.62; P < .001) and multivariable (OR, 3.78; 95% CI, 1.82-7.85; P < .001) analyses. Additionally, those with a DIC score of ≥3 vs <3 had increased 1-year mortality with a hazard ratio of 3.55 (95% CI, 1.46-8.64; P = .005). CONCLUSIONS: A DIC score of ≥3 was an independent predictor for both vasopressor use and mortality in this pediatric cohort, distinct from the adult overt DIC score cutoff of ≥5.
Asunto(s)
Coagulación Intravascular Diseminada/diagnóstico , Coagulación Intravascular Diseminada/mortalidad , Sepsis/diagnóstico , Sepsis/mortalidad , Adolescente , Niño , Preescolar , Estudios de Cohortes , Coagulación Intravascular Diseminada/tratamiento farmacológico , Coagulación Intravascular Diseminada/etiología , Femenino , Humanos , Unidades de Cuidado Intensivo Pediátrico , Masculino , Modelos de Riesgos Proporcionales , Curva ROC , Sistema de Registros , Respiración Artificial/estadística & datos numéricos , Sepsis/complicaciones , Vasoconstrictores/uso terapéuticoRESUMEN
BACKGROUND: Resuscitation of septic patients regarding goals, monitoring aspects and therapy is highly variable. Our aim was to characterize cardiovascular and fluid management of sepsis in Argentina, a low and middle-income country (LMIC). Furthermore, we sought to test whether the utilization of dynamic tests of fluid responsiveness, as a guide for fluid therapy after initial resuscitation in patients with persistent or recurrent hypoperfusion, was associated with decreased mortality. METHODS: Secondary analysis of a national, multicenter prospective cohort study (n = 787) fulfilling Sepsis-3 definitions. Epidemiological characteristics, hemodynamic management data, type of fluids and vasopressors administered, physiological variables denoting hypoperfusion, use of tests of fluid responsiveness, and outcomes, were registered. Independent predictors of mortality were identified with logistic regression analysis. RESULTS: Initially, 584 of 787 patients (74%) had mean arterial pressure (MAP) < 65 mm Hg and/or signs of hypoperfusion and received 30 mL/kg of fluids, mostly normal saline (53%) and Ringer lactate (35%). Vasopressors and/or inotropes were administered in 514 (65%) patients, mainly norepinephrine (100%) and dobutamine (9%); in 22%, vasopressors were administered before ending the fluid load. After this, 413 patients (53%) presented persisting or recurrent hypotension and/or hypoperfusion, which prompted administration of additional fluid, based on: lactate levels (66%), urine output (62%), heart rate (54%), central venous O2 saturation (39%), central venous-arterial PCO2 difference (38%), MAP (31%), dynamic tests of fluid responsiveness (30%), capillary-refill time (28%), mottling (26%), central venous pressure (24%), cardiac index (13%) and/or pulmonary wedge pressure (3%). Independent predictors of mortality were SOFA and Charlson scores, lactate, requirement of mechanical ventilation, and utilization of dynamic tests of fluid responsiveness. CONCLUSIONS: In this prospective observational study assessing the characteristics of resuscitation of septic patients in Argentina, a LMIC, the prevalent use of initial fluid bolus with normal saline and Ringer lactate and the use of norepinephrine as the most frequent vasopressor, reflect current worldwide practices. After initial resuscitation with 30 mL/kg of fluids and vasopressors, 413 patients developed persistent or recurrent hypoperfusion, which required further volume expansion. In this setting, the assessment of fluid responsiveness with dynamic tests to guide fluid resuscitation was independently associated with decreased mortality.
RESUMEN
PURPOSE: Our main objective was to use the Maximum Acute Gastrointestinal Injury Score (AGImax) to evaluate the prognostic capability of gastrointestinal dysfunction (GID), on hospital mortality in patients on mechanical ventilation (MV) requiring vasopressors. A secondary goal was to analyze the relationship between AGImax and vasopressor dosage with increasing caloric intake. MATERIALS AND METHODS: Prospective multicenter cohort study in ten ICUs across Argentina. Consecutive adult patients on MV, requiring vasopressors and receiving enteral nutrition (EN) were included. AGImax was identified (I-IV) using a modified AGI score. Comparisons of clinical and outcome variables were performed in 3 predetermined EN-groups: <10 kcal/kg/d, ≥10 to <20 kcal/kg/d, or ≥ 20 kcal/kg/d. RESULTS: A total of 494 patients met all inclusion criteria. Forty-four percent of patients had severe AGImax and 17% received <10 kcal/kg/day, indicating more severity and higher mortality. Notable independent predictors of mortality were AGImax, vasopressors, and caloric intake. PN was the only factor which had an inverse relationship to mortality. CONCLUSIONS: In this population, patients with AGImax III-IV were significantly associated with lower caloric intake and greater hospital mortality, highlighting the importance of AGI as a prognostic tool. As PN was linked with lower mortality, it could be an option to explore in further studies.
Asunto(s)
Ingestión de Energía , Tracto Gastrointestinal/lesiones , Puntaje de Gravedad del Traumatismo , Choque/terapia , Vasopresinas/uso terapéutico , Adulto , Argentina , Estudios de Cohortes , Femenino , Humanos , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Estudios Prospectivos , Respiración Artificial , Choque/mortalidad , Vasopresinas/administración & dosificaciónRESUMEN
Se presentan tres casos de gangrena seca ocurridos en el invierno austral del 2018. El primero corresponde a un varón de 37 años, portador de vasculitis por crioglobulinemia y enfermedad celiaca silente, que desarrolla gangrena seca en manos y pies. El segundo es una mujer de 40 años que consulta por gangrena seca de manos y pies, sin etiología demostrable. El tercero es un varón de 38 años que ingresa por choque séptico de origen neumónico que requiere tratamiento con vasopresores desarrollando gangrena seca de manos y pies. A pesar que los tres casos tienen etiología diferente, coincidieron con temperaturas muy frías (media 6° C), inusuales para el clima tropical del Paraguay.
We present three cases of dry gangrene occurred in the southern winter of 2018. The first corresponds to a 37-year-old man, carrier of vasculitis due to cryoglobulinemia and silent celiac disease, which develops dry gangrene in hands and feet. The second is a 40-year-old woman who consults for dry gangrene of hands and feet, without demonstrable etiology. The third is a 38-year-old male admitted for septic shock of pulmonary origin that requires treatment with vasopressors developing dry gangrene of the hands and feet. Although the three cases have a different etiology, they coincided with very cold temperatures (average 6 °C), unusual for the tropical climate of Paraguay.
RESUMEN
IntroductionEmergency physicians are using bolus-dose vasopressors to temporize hypotensive patients until more definitive blood pressure support can be established. Despite a paucity of clinical outcome data, emergency department applications are expanding into the prehospital setting. This series presents two cases of field expedient vasopressor use by emergency medicine providers for preflight stabilization during aeromedical evacuation to a hospital ship as part of the United States Navy disaster response in Puerto Rico. A critical approach and review of the literature are discussed.Case ReportTwo critically ill patients were managed in an austere environment as a result of the devastation from Hurricane Maria (Yabucoa, Puerto Rico; 2017). They both exhibited signs of respiratory distress, hemodynamic instability, and distributive shock requiring definitive airway management and hemodynamic support prior to aeromedical evacuation.DiscussionThe novel use of field expedient vasopressors prior to induction for rapid sequence intubation was successfully and safely employed in both cases. Both patients had multiple risk factors for peri-induction cardiac arrest given their presenting hemodynamics. Despite their illness severity, both patients were induced, transported, and ultimately admitted to the intensive care unit (ICU) in stable condition following administration of the field expedient vasopressors.Conclusion:Field expedient vasopressors were safely and effectively employed in an austere field environment during a disaster response. This case series contributes to the growing body of literature of safe bolus-dose vasopressor use by emergency physicians to temporize hypotensive patients in resource-constrained situations. HardwickJM, MurnanSD, Morrison-PonceDP, DevlinJJ. Field expedient vasopressors during aeromedical evacuation: a case series from the Puerto Rico disaster response. Prehosp Disaster Med. 2018;33(6):668-672.
Asunto(s)
Broncodilatadores/uso terapéutico , Tormentas Ciclónicas , Epinefrina/uso terapéutico , Síndrome de Dificultad Respiratoria/terapia , Anciano , Ambulancias Aéreas , Broncodilatadores/administración & dosificación , Servicios Médicos de Urgencia , Epinefrina/administración & dosificación , Femenino , Humanos , Intubación Intratraqueal , Puerto RicoRESUMEN
Resumen: Introducción: El uso de vasopresores en choque séptico es parte fundamental del tratamiento. El uso de un puntaje que integre los múltiples vasopresores e inotrópicos como LVIS (levosimendan vasopressor inotropic score), puede ser de utilidad para el seguimiento y pronóstico de estos pacientes. Se ha estudiado en población pediátrica y no ha sido validada en población adulta. Material y métodos: Estudio retrospectivo, longitudinal, retrolectivo en pacientes adultos admitidos a UCI con diagnóstico de choque séptico con el fin de investigar si el puntaje LVIS es capaz de predecir mortalidad y lesión renal aguda. Seguimiento a 30 días. Resultados: Incluimos 77 pacientes, 24 (21.2%) pacientes murieron y 41 (53.23%) presentaron lesión renal aguda. Se observó un AUC (área bajo la curva) para LVIS 0.89 con un punto de corte de 21.3 (sensibilidad 50% y especificidad de 82%). El puntaje LVIS > 21.3 con RR 2.09 (IC95% 1.15-3.7, p = 0.003) y un HR de 3.8 (IC95% 1.5-9.3, p = 0.003), LR+ 2.81 y LR- 0.61 para mortalidad. LVIS no fue significativo para predecir LRA (lesión renal aguda). Conclusiones: LVIS es útil para predecir mortalidad en choque séptico, con un punto de corte 21.3. Es necesario continuar estudios para validarlo en población adulta con otras formas de choque.
Abstract: Introduction: Vasopressors have a fundamental roll in the treatment of septic shock. LVIS (levosimendan vasopressor inotropic score) as a score that integrates the main vasopressors and inotropic drugs may be useful for monitoring and prognosis. It's been studied in pediatric population, but not validated in adult patients so far. Material and methods: Retrospective, longitudinal, retrolective study in adults admitted in ICU with septic shock. We looked to investigate if LVIS score is useful to predict mortality and acute kidney injury in ICU, with a follow-up of 30 days. Results: We included 77 patients, 24 (21.2%) patients died and 41 (53.23%) developed acute kidney injury. LVIS had an AUC of 0.89 with a cut-off of 21.3 (50% sensitivity and 82% of specificity). LVIS score above the cut-off 21.3, had RR 2.09 (CI95% 1.15-3.7, p = 0.003), HR de 3.8 (CI 1.5-9.3, p = 0.003), LR+ 2.81 and LR- 0.61 for mortality. LVIS could not predict AKI (acute kidney). Conclusions: LVIS score is useful to predict mortality in patients with septic shock, with a cut-off of 21.3. More research is left to be done to validate this score in other forms of shock in adult population.
Resumo: Introdução: O uso de vasopressores no choque séptico é uma parte fundamental do tratamento. O uso de um escore que integra múltiplos vasopressores e drogas inotrópicas como o LVIS (Levosimendan Vasopressor Inotropic Score), pode ser útil para o acompanhamento e prognóstico desses pacientes. Foi estudado na população pediátrica e não foi validado na população adulta. Material e métodos: Estudo retrospectivo, longitudinal, retrolectivo em pacientes adultos admitidos na UTI com o diagnóstico de choque séptico para investigar se o escore LVIS é capaz de predizer a mortalidade e a lesão renal aguda em um acompanhamento de 30 dias. Resultados: Foram incluídos 77 pacientes, 24 (21.2%) pacientes morreram e 41 (53.23%) apresentaram lesão renal aguda. Uma AUC (área sob a curva) foi observada para LVIS 0.89 com um ponto de corte de 21.3 (sensibilidade 50% e especificidade 82%). O escore LVIS > 21.3 com RR 2.09 (IC95% 1.15-3.7, p = 0.003) e uma HR de 3.8 (IC95% 1.5-9.3, p = 0.003), LR + 2.81 e LR -0.61 para mortalidade. O LVIS não foi significativa na predição da LRA (lesão renal aguda). Conclusões: O LVIS é útil para prever a mortalidade no choque séptico, com um ponto de corte de 21.3. É necessário continuar os estudos para validá-lo na população adulta com outras formas de choque.
RESUMEN
Resumen: El sistema cardiovascular es un sistema dinámico cuya función es asegurar un adecuado suministro de oxígeno, nutrientes y hormonas a los tejidos, necesarios para el metabolismo celular, además sintetiza y modifican los componentes vasoactivos los cuales regulan el tono vascular y la función miocárdica. Estos componentes vasoactivos son fundamentales en el manejo del paciente pediátrico en estado crítico con falla cardiaca y choque en los cuales se ha comprobado sus efectos benéficos, sin embargo, su uso y abuso trae consigo efectos nocivos, tales como mayor riesgo de arritmias, aumento el consumo miocárdico de oxígeno lo cual podría favorecer la presencia de isquemia. Por lo tanto, es preciso conocer el mecanismo de acción de los distintos tipos de agentes vasoactivos, así como las indicaciones de dichos fármacos para minimizar dichos efectos. El propósito de esta revisión es describir la farmacología y las aplicaciones clínicas de los agentes inotrópicos y Vasopresores en el paciente pediátrico en estado crítico. © 2017 Instituto Nacional de Cardiolog´ıa Ignacio Cha´vez. Publicado por Masson Doyma Me´xico S.A. Este es un art´ıculo Open Access bajo la licencia CC BY-NC-ND (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Abstract: The cardiovascular system is a dynamic system, which is required to ensure adequate delivery of oxygen, nutrients, and hormones to the tissues that are necessary for cell metabolism. It also synthesises and modifies the vasoactive components that regulate vascular tone and myocardial function. These vasoactive components have demonstrated their beneficial effects in the management of paediatric patients in a critical condition with heart failure and shock. However, their use and abuse brings harmful effects, increases mortality, and is associated with arrhythmias. An increase in myocardial oxygen consumption favours the presence of ischaemia, therefore it is necessary to know the mechanism of action and indications of these drugs to minimise their harmful effects. The purpose of this review is to describe the pharmacology and clinical applications of inotropic and vasopressor agents in the paediatric patient in acritical condition. © 2017 Instituto Nacional de Cardiologìa Ignacio Chàvez. Published by Masson Doyma Mèxico S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).
Asunto(s)
Humanos , Niño , Vasoconstrictores/uso terapéutico , Cardiotónicos/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológicoRESUMEN
The cardiovascular system is a dynamic system, which is required to ensure adequate delivery of oxygen, nutrients, and hormones to the tissues that are necessary for cell metabolism. It also synthesises and modifies the vasoactive components that regulate vascular tone and myocardial function. These vasoactive components have demonstrated their beneficial effects in the management of paediatric patients in a critical condition with heart failure and shock. However, their use and abuse brings harmful effects, increases mortality, and is associated with arrhythmias. An increase in myocardial oxygen consumption favours the presence of ischaemia, therefore it is necessary to know the mechanism of action and indications of these drugs to minimise their harmful effects. The purpose of this review is to describe the pharmacology and clinical applications of inotropic and vasopressor agents in the paediatric patient in acritical condition.
Asunto(s)
Cardiotónicos/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , Vasoconstrictores/uso terapéutico , Niño , HumanosRESUMEN
INTRODUCCIÓN: En Bolivia existe dificultad en la disponibilidad del medicamento como es la fenilefrina, surge la inmediata necesidad de evaluar otro medicamento con características farmacológicas que son útiles para este fin. OBJETIVOS: Comparar el uso de norepinefrina versus etilefrina como prevención de hipotensión materna posterior a anestesia raquídea en cesárea electiva. MÉTODOS: Se realizó un ensayo clínico randomizado, doble ciego, en 126 pacientes sometidas a cesárea bajo anestesia raquídea divididas en tres grupos de 42 pacientes. Grupo E recibió Etilefrina bolo 2mg, grupo Norepinefrina Bolo (NB) 5µg y grupo Norepinefrina en Infusión (NI) 0,01µg/kg/min para controlar la hipotensión, se realizó control de presión arterial media, frecuencia cardiaca, análisis de costo del medicamento y puntuaciones de APGAR. El análisis estadístico se realizó en SPSS 22 y Microsoft Exce® 2010. RESULTADOS: La presión arterial media fueron similares hasta antes del nacimiento, posterior es mejor controlado con la infusión de norepinefrina (p 0,000). La frecuencia cardiaca más estable en el grupo de NB (p 0,000). No presentó efectos adversos maternos y en el recién nacido. Se evidencia un costo más elevado a usar Etilefrina en bolo 42,5 ± 8,36 (bolivianos) que usar norepinefrina en infusión 0,50 ± 0,15 (bolivianos) y norepinefrina en bolo 0,45 ± 0,14 (bolivianos) existe una diferencia estadísticamente significativa (p 0,000). CONCLUSIONES: Es eficaz la utilización de norepinefrina en infusión en comparación a etilefrina debido a que se controló mejor las variables hemodinámicas con un costo muy bajo para el manejo de la hipotensión materna posterior a anestesia raquídea.
INTRODUCTION: In Bolivia there is the difficulty on availability of the drug such as phenylephrine, there is the immediate need to evaluate another drug with pharmacological characteristics that are useful for this purpose OBJETIVE: To compare the use of norepinephrine versus etilefrine as prevention of maternal hypotension after spinal anesthesia in elective cesarean section. METHODS: Was conducted a randomized double-blind clinical trial in 126 patients undergoing Cesarean section under spinal anesthesia divided into three groups of 42 patients. Group E received Etilefrine bolus 2 mg, group NB norepinephrine bolus 5 µg and group NI norepinephrine infusion 0,01µg /kg/min to control hypotension control of mean arterial pressure, heart rate, were performed an analysis of drug cost and scores of APGAR. Was performed the statistical analysis in SPSS 22 and Microsoft Excel 2010. RESULTS: Mean arterial blood pressure was similar until before birth, later it is better controlled with norepinephrine infusion (p 0,000). The most stable heart rate in the NB group (p 0,000). There were maternal adverse effects and in the newborn. There is a higher cost to use bolus ethylephrine 42.5 ± 8.36 (bolivianos) than to use norepinephrine in infusion 0.50 ± 0.15 (bolivianos) and bolus norepinephrine 0.45 ± 0.14 (bolivianos) there is a statistically significant difference (p 0,000). CONCLUSIONS: The use of norepinephrine in infusion compared to etilefrine is effective because the hemodynamic variables were better controlled at a very low cost for the management of maternal hypotension after spinal anesthesia.
Asunto(s)
Humanos , Bupivacaína/administración & dosificación , Cesárea/métodos , Anestesia RaquideaRESUMEN
Los beneficios de la nutrición enteral, especialmente de la nutrición enteral precoz, están documentados. Sin embargo, aún existen controversias al momento de decidir el inicio del soporte nutricional por esta vía en pacientes críticos hemodinámicamente inestables, que están recibiendo agentes vasopresores o inotrópicos. La experiencia clínica en seres humanos sugiere que la provisión de nutrición enteral después de un período de hipotensión puede reducir la lesión o el grado de isquemia del intestino delgado. Sobre la base de la evidencia, el inicio cauteloso de la nutrición enteral con sustancias vasoactivas es posible y seguro. No obstante, se necesitan más estudios para poder profundizar en los aspectos relativos al inicio y la implementación del soporte nutricional.(AU)
Benefits of enteral nutrition, especially early enteral nutrition, have been well documented. However, there are still controversies when deciding the initiation of nutritional support by this route in critical hemodynamically unstable patients who are receiving vasopressor or inotropic drugs. Clinical experience in humans suggests that provision of enteral nutrition after a period of hypotension may reduce injury or the extent of small bowel ischemia. Based on the evidence, cautious onset of enteral nutrition with vasoactive substances is possible and safe. However, more studies are needed to know the aspects related to the initiation and implementation of nutritional support. (AU)
Asunto(s)
Humanos , Vasoconstrictores , Nutrición Enteral , Cuidados Críticos , HipotensiónRESUMEN
OBJECTIVES: To assess the impact of vasopressin on the microcirculation and to develop a predictive model to estimate the probability of microcirculatory recruitment in patients with septic shock. METHODS: This prospective interventional study included patients with septic shock receiving noradrenaline for less than 48 hours. We infused vasopressin at 0.04 U/min for one hour. Hemodynamic measurements, including sidestream dark-field imaging, were obtained immediately before vasopressin infusion, 1 hour after vasopressin infusion and 1 hour after vasopressin withdrawal. We defined patients with more than a 10% increase in total vascular density and perfused vascular density as responders. ClinicalTrials.gov: NCT02053675. RESULTS: Eighteen patients were included, and nine (50%) showed improved microcirculation after infusion of vasopressin. The noradrenaline dose was significantly reduced after vasopressin (p=0.001) and was higher both at baseline and during vasopressin infusion in the responders than in the non-responders. The strongest predictor for a favorable microcirculatory response was the dose of noradrenaline at baseline (OR=4.5; 95% CI: 1.2-17.0; p=0.027). For patients using a noradrenaline dose higher than 0.38 mcg/kg/min, the probability that microcirculatory perfusion would be improved with vasopressin was 53% (sensitivity 78%, specificity 77%). CONCLUSIONS: In patients with septic shock for no longer than 48 h, administration of vasopressin is likely to result in an improvement in microcirculation when the baseline noradrenaline dose is higher than 0.38 mcg/kg/min.
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Choque Séptico/tratamiento farmacológico , Vasoconstrictores/administración & dosificación , Vasopresinas/administración & dosificación , Norepinefrina/administración & dosificación , Microcirculación/efectos de los fármacos , Choque Séptico/fisiopatología , Vasoconstrictores/farmacología , Vasopresinas/farmacología , Norepinefrina/farmacología , Estudios Prospectivos , Quimioterapia CombinadaRESUMEN
La hipotensión asociada con la vasodilatación inducida por el uso de agentes anestésicos es muy frecuente, un fenómeno que ha motivado la utilización casi generalizada de vasopresores, con la finalidad de restaurar la presión sanguínea a los niveles registrados antes de la anestesia. En Australia, entre todas las medicaciones que se usan en la anestesia, el costo de los vasopresores es un factor significativo en los costos de los sistemas de salud. La utilización de vasopresores debe basarse en los posibles beneficios y riesgos asociados. Desde hace tiempo se acepta que la presión arterial debe mantenerse con la finalidad de preservar la perfusión. Sin embargo, la evaluación detallada indica que este concepto podría surgir de la interpretación errónea de las leyes básicas de la física, como las leyes de Newton y de Ohm. En este trabajo se propone, en función de los principios de la física, que sólo las fuerzas pueden motivar el aceleramiento de los objetos. Para que la presión sea un conductor del flujo, debería ser una fuerza. Sin embargo, la presión es el resultado de fuerzas que actúan sobre una superficie determinada y, por ende, no representa en sí misma una fuerza y no puede ser un conductor de flujo. El flujo sanguíneo es resultado del equilibrio entre las fuerzas de propulsión y de resistencia; en este contexto se debe reconsiderar el supuesto beneficio de aumentar las fuerzas de resistencia, un fenómeno que, en realidad, motivará una reducción del flujo. En el estudio se cuestiona el uso de vasopresores, como también la relación básica, ampliamente aceptada, entre la presión sanguínea y el flujo sanguíneo.
Hypotension resulting from vasodilatation associated with administration of anaesthetic agents is very common. This has resulted in the almost ubiquitous use of vasopressors with a view to restoring blood pressure to pre-anaesthesia levels. In Australia, of all the medications used in anaesthesia, the cost of vasopressors is a significant factor in contributing to healthcare costs. The rationale for use of vasopressors warrants consideration with regard to their benefits as well as potential harm arising from their use. It has long been accepted that blood pressure needs to be maintained in order to maintain perfusion. However, on close scrutiny such thinking may simply be a misinterpretation of the basic laws of physics with respect to both Newton's laws and Ohm's law. This article develops the physics-based argument that only forces can cause objects to accelerate. For pressure to be a driver of flow it must therefore be a force. However, pressure is the result of forces acting over an area, and consequently is not a force in itself. Therefore, it cannot be a driver of flow. Blood flow is the result of the balance of propulsive and resistive forces, which raises the question as to the benefit of increasing resistive forces, which in fact will reduce flow. The use of vasopressors is challenged in this article as is the basic accepted relationship between blood pressure and blood flow.
Asunto(s)
Humanos , Perfusión , Flujo Sanguíneo Regional , Vasoconstrictores , Vasodilatación , Presión Sanguínea , Presión Arterial , Hipotensión , Anestésicos , Evolución ClínicaRESUMEN
Resumen: Se ha considerado que los betabloqueadores pueden reducir la sobreestimulación adrenérgica en pacientes sépticos. Se diseñó este estudio retrospectivo de casos y controles para identificar la relación del consumo crónico de betabloqueadores en pacientes que desarrollaron sepsis y choque séptico tratados en UTI y la mortalidad a 30 días. Se incluyeron 104 pacientes dividiéndose en dos grupos: betabloqueadores (n = 16) y control (n = 88). Los pacientes del grupo de estudio no presentaron diferencia de mortalidad en relación con el control (p = 0.99); sin embargo, el SOFA cardiovascular fue mayor (p = 0.05), requirieron mayor dosis de vasopresores (p = 0.18) y mayor tiempo de estancia en UTI (p = 0.11). El consumo crónico de betabloqueadores no fue factor de protección para mortalidad en pacientes sépticos.
Abstract: It has been considered that beta-blockers are used to reduce adrenergic overstimulation in septic patients. Therefore, we designed a case-control study to identify if chronic use of beta-blockers is related to less 30-day mortality among septic patients. We review medical records of ICU admission. In total, we included 104 patients divided into two groups: beta-blockers (n = 16) and control (n = 88). Patients in the study group showed no difference in mortality relative to control (p = 0.99), however the cardiovascular SOFA was higher (p = 0.05), required higher dose of vasopressors (p = 0.18) and longer stay in UTI (p = 0.11). The chronic use of beta-blockers was not protective factor for mortality in septic patients.
Resumo: Considerou-se que os betabloqueadores podem reduzir a superestimulação adrenérgica em pacientes sépticos. Assim, desenhou-se um estudo retrospectivo de caso e controle para identificar a relação de consumo crônico de betabloqueadores em pacientes que desenvolveram septicemia e choque séptico tratados na UTI e mortalidade aos 30 dias. Foram incluídos 104 pacientes divididos em dois grupos: betabloqueadores (n = 16) e de controle (n = 88). Os pacientes no grupo do estudo não demonstraram diferença na mortalidade em relação ao grupo de controle (p = 0.99), no entanto o SOFA cardiovascular foi maior (p = 0.05), necessitaram uma dose mais elevada de vasopressores (p = 0.18) e maior tempo de UTI (p = 0.11). O consumo crónico de betabloqueadores não foi o fator de proteção para a mortalidade em pacientes sépticos.
RESUMEN
This paper summarizes the pharmacologic properties of vasoactive medications used in the treatment of shock, including the inotropes and vasopressors. The clinical application of these therapies is discussed and recent studies describing their use and associated outcomes are also reported. Comprehension of hemodynamic principles and adrenergic and non-adrenergic receptor mechanisms are salient to the appropriate therapeutic utility of vasoactive medications for shock. Vasoactive medications can be classified based on their direct effects on vascular tone (vasoconstriction or vasodilation) and on the heart (presence or absence of positive inotropic effects). This classification highlights key similarities and differences with respect to pharmacology and hemodynamic effects. Vasopressors include pure vasoconstrictors (phenylephrine and vasopressin) and inoconstrictors (dopamine, norepinephrine, and epinephrine). Each of these medications acts as vasopressors to increase mean arterial pressure by augmenting vascular tone. Inotropes include inodilators (dobutamine and milrinone) and the aforementioned inoconstrictors. These medications act as inotropes by enhancing cardiac output through enhanced contractility. The inodilators also reduce afterload from systemic vasodilation. The relative hemodynamic effect of each agent varies depending on the dose administered, but is particularly apparent with dopamine. Recent large-scale clinical trials have evaluated vasopressors and determined that norepinephrine may be preferred as a first-line therapy for a broad range of shock states, most notably septic shock. Consequently, careful selection of vasoactive medications based on desired pharmacologic effects that are matched to the patient's underlying pathophysiology of shock may optimize hemodynamics while reducing the potential for adverse effects.